Compare HASI & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HASI | ACLX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2012 | 2022 |
| Metric | HASI | ACLX |
|---|---|---|
| Price | $37.36 | $114.78 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 15 |
| Target Price | $42.38 | ★ $115.85 |
| AVG Volume (30 Days) | 743.5K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $400,502,000.00 | $22,286,000.00 |
| Revenue This Year | $61.10 | $397.53 |
| Revenue Next Year | $250.69 | $123.06 |
| P/E Ratio | $26.06 | ★ N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $21.98 | $47.86 |
| 52 Week High | $40.01 | $114.91 |
| Indicator | HASI | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 81.34 |
| Support Level | $35.18 | $66.06 |
| Resistance Level | $40.01 | $114.86 |
| Average True Range (ATR) | 1.02 | 0.28 |
| MACD | 0.07 | -1.54 |
| Stochastic Oscillator | 94.29 | 73.44 |
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.